MorphoSys AG (ETR:MOR) Given a €59.00 Price Target at HSBC Holdings plc

HSBC Holdings plc set a €59.00 ($67.82) price target on MorphoSys AG (ETR:MOR) in a report released on Friday. The brokerage currently has a neutral rating on the stock.

Several other research analysts have also issued reports on MOR. Berenberg Bank set a €68.00 ($78.16) target price on MorphoSys AG and gave the company a buy rating in a research report on Thursday, May 25th. Independent Research GmbH set a €77.00 ($88.51) target price on MorphoSys AG and gave the company a buy rating in a research report on Monday, May 29th. Commerzbank Ag set a €76.00 ($87.36) target price on MorphoSys AG and gave the company a buy rating in a research report on Tuesday, May 30th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($63.22) target price on MorphoSys AG and gave the company a neutral rating in a research report on Tuesday, June 6th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of €67.00 ($77.01).

MorphoSys AG (ETR MOR) traded up 0.776% during midday trading on Friday, hitting €67.419. The company had a trading volume of 6,447 shares. The stock’s market capitalization is €1.94 billion. MorphoSys AG has a 52 week low of €35.72 and a 52 week high of €68.33. The stock has a 50 day moving average price of €62.72 and a 200-day moving average price of €54.66.

ILLEGAL ACTIVITY NOTICE: “MorphoSys AG (ETR:MOR) Given a €59.00 Price Target at HSBC Holdings plc” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.com-unik.info/2017/07/17/morphosys-ag-etrmor-given-a-59-00-price-target-at-hsbc-holdings-plc.html.

MorphoSys AG Company Profile

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company’s operating segments include Proprietary Development and Partnered Discovery.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

What are top analysts saying about MorphoSys AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MorphoSys AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit